Physician profile
Junaid Khan
NPI 1912163809
$5,526.67
in general payments reported to CMS, 2019-2025
27 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,266 · 2020: $284 · 2021: $261 · 2022: $774 · 2023: $1,134 · 2024: $781 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,860 · Education: $81.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,860.39 |
| Education | $81.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,811.49 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $547.34 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.56 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Amgen INC. | $423.73 | 2022-2025 | Tezspire |
| Genzyme Corporation | $394.47 | 2019-2025 | |
| Electromed, INC. | $242.42 | 2019-2024 | Smartvest |
| Mallinckrodt Hospital Products INC. | $165.67 | 2023-2024 | Acthar |
| Grifols USA, LLC | $156.86 | 2021-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $151.52 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $135.16 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $124.09 | 2019-2023 | Dupixent |
| Insmed, INC. | $111.49 | 2019-2025 | Arikayce |
| Novartis Pharmaceuticals Corporation | $110.84 | 2019-2020 | |
| Shire North American Group INC | $94.33 | 2019 | |
| Sunovion Pharmaceuticals INC. | $62.45 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $61.39 | 2023-2024 | Epic |
| Pulmonx Corporation | $61.37 | 2021-2023 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Actelion Pharmaceuticals US, INC. | $58.31 | 2024-2025 | Opsynvi, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $55.98 | 2020-2023 | Glassia |
| Teva Pharmaceuticals USA, INC. | $53.42 | 2020-2022 | |
| Circassia INC. | $41.10 | 2019 | |
| Mylan Specialty L.P. | $40.64 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.84 | 2019 | |
| Tactile Systems Technology INC | $21.24 | 2025 | Nimbl, Flexitouch Plus |
| Inspire Medical Systems, INC. | $21.09 | 2025 | Inspire |
| Mallinckrodt Enterprises LLC | $17.51 | 2019 | |
| Philips North America LLC | $15.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junaid Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.